Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Can-Fite has received clearance from the Israeli Ministry of Health to commence a Phase IIb study of its drug candidate Namodenoson in the treatment of NASH.